You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Using data from cancer registries, investigators saw apparent disparities in the surgical interventions and treatments used for breast cancer patients with inherited cancer risk.
The foundation-funded initiative from Jackson Laboratories has advanced a model for educating oncologists and providing access to tumor genomic profiling in the community setting.
A new analysis has provided evidence that adjuvant lung cancer immunotherapy benefits those with lingering ctDNA, but not necessary those without.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Circulating tumor DNA detection in stage III colon cancer patients after surgery and adjuvant chemotherapy coincided with a rise in recurrence risk.
A juvenile leukemia patient with a rare FLT3 fusion was treated with precision therapy after researchers used a DNA panel and RNA-seq to analyze his disease.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
Investigators used gene panel testing to assess hereditary breast and ovarian cancer risk in African American women with breast cancer, uncovering potential gaps in test access.